OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Predictive biomarkers for response to immune checkpoint inhibition
Benjamin Shum, James Larkin, Samra Turajlic
Seminars in Cancer Biology (2021) Vol. 79, pp. 4-17
Closed Access | Times Cited: 96
Benjamin Shum, James Larkin, Samra Turajlic
Seminars in Cancer Biology (2021) Vol. 79, pp. 4-17
Closed Access | Times Cited: 96
Showing 1-25 of 96 citing articles:
Review of the Immune Checkpoint Inhibitors in the Context of Cancer Treatment
Norah A. Alturki
Journal of Clinical Medicine (2023) Vol. 12, Iss. 13, pp. 4301-4301
Open Access | Times Cited: 50
Norah A. Alturki
Journal of Clinical Medicine (2023) Vol. 12, Iss. 13, pp. 4301-4301
Open Access | Times Cited: 50
A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists
Jessalyn J. Baljon, Alexander J. Kwiatkowski, Hayden M. Pagendarm, et al.
ACS Nano (2024) Vol. 18, Iss. 9, pp. 6845-6862
Open Access | Times Cited: 35
Jessalyn J. Baljon, Alexander J. Kwiatkowski, Hayden M. Pagendarm, et al.
ACS Nano (2024) Vol. 18, Iss. 9, pp. 6845-6862
Open Access | Times Cited: 35
Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancer
Daniiar Dyikanov, A. V. Zaitsev, Т.В. Васильева, et al.
Cancer Cell (2024) Vol. 42, Iss. 5, pp. 759-779.e12
Open Access | Times Cited: 21
Daniiar Dyikanov, A. V. Zaitsev, Т.В. Васильева, et al.
Cancer Cell (2024) Vol. 42, Iss. 5, pp. 759-779.e12
Open Access | Times Cited: 21
cGAS-STING pathway mediates activation of dendritic cell sensing of immunogenic tumors
Guohao Li, Xiangqian Zhao, Zuda Zheng, et al.
Cellular and Molecular Life Sciences (2024) Vol. 81, Iss. 1
Open Access | Times Cited: 17
Guohao Li, Xiangqian Zhao, Zuda Zheng, et al.
Cellular and Molecular Life Sciences (2024) Vol. 81, Iss. 1
Open Access | Times Cited: 17
PD-L1 testing by immunohistochemistry in Immuno-Oncology
Semir Vranić, Zoran Gatalica
Bosnian Journal of Basic Medical Sciences (2022)
Open Access | Times Cited: 60
Semir Vranić, Zoran Gatalica
Bosnian Journal of Basic Medical Sciences (2022)
Open Access | Times Cited: 60
NLRP3 promotes immune escape by regulating immune checkpoints: A pan-cancer analysis
Yue Ding, Yi‐Lin Yan, Yihui Dong, et al.
International Immunopharmacology (2022) Vol. 104, pp. 108512-108512
Open Access | Times Cited: 41
Yue Ding, Yi‐Lin Yan, Yihui Dong, et al.
International Immunopharmacology (2022) Vol. 104, pp. 108512-108512
Open Access | Times Cited: 41
TheMarker: a comprehensive database of therapeutic biomarkers
Yintao Zhang, Ying Zhou, Yuan Zhou, et al.
Nucleic Acids Research (2023) Vol. 52, Iss. D1, pp. D1450-D1464
Open Access | Times Cited: 37
Yintao Zhang, Ying Zhou, Yuan Zhou, et al.
Nucleic Acids Research (2023) Vol. 52, Iss. D1, pp. D1450-D1464
Open Access | Times Cited: 37
Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases
Eftychia Chatziioannou, Jana Roßner, Thazin New Aung, et al.
EBioMedicine (2023) Vol. 93, pp. 104644-104644
Open Access | Times Cited: 23
Eftychia Chatziioannou, Jana Roßner, Thazin New Aung, et al.
EBioMedicine (2023) Vol. 93, pp. 104644-104644
Open Access | Times Cited: 23
The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes
David M. Gershenson, Charlotte C. Sun, Shannon N. Westin, et al.
Gynecologic Oncology (2022) Vol. 165, Iss. 3, pp. 560-567
Closed Access | Times Cited: 36
David M. Gershenson, Charlotte C. Sun, Shannon N. Westin, et al.
Gynecologic Oncology (2022) Vol. 165, Iss. 3, pp. 560-567
Closed Access | Times Cited: 36
Targeting STING for cancer immunotherapy: From mechanisms to translation
Ruilei Huang, Qian Ning, Jihui Zhao, et al.
International Immunopharmacology (2022) Vol. 113, pp. 109304-109304
Closed Access | Times Cited: 33
Ruilei Huang, Qian Ning, Jihui Zhao, et al.
International Immunopharmacology (2022) Vol. 113, pp. 109304-109304
Closed Access | Times Cited: 33
A Novel Lactate Metabolism-Related Gene Signature for Predicting Clinical Outcome and Tumor Microenvironment in Hepatocellular Carcinoma
Yue Li, Huanye Mo, Shengli Wu, et al.
Frontiers in Cell and Developmental Biology (2022) Vol. 9
Open Access | Times Cited: 31
Yue Li, Huanye Mo, Shengli Wu, et al.
Frontiers in Cell and Developmental Biology (2022) Vol. 9
Open Access | Times Cited: 31
Expanding Therapeutic Opportunities for Extrapulmonary Neuroendocrine Carcinoma
Melissa Frizziero, Elaine Kilgour, Kathryn Simpson, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 10, pp. 1999-2019
Open Access | Times Cited: 28
Melissa Frizziero, Elaine Kilgour, Kathryn Simpson, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 10, pp. 1999-2019
Open Access | Times Cited: 28
OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum
Tetje C. van der Sluis, Guillaume Beyrend, Esmé T.I. van der Gracht, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 3, pp. 100939-100939
Open Access | Times Cited: 15
Tetje C. van der Sluis, Guillaume Beyrend, Esmé T.I. van der Gracht, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 3, pp. 100939-100939
Open Access | Times Cited: 15
Advances in nano-immunotherapy for hematological malignancies
Jian Xu, Wenqi Liu, Fengjuan Fan, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 5
Jian Xu, Wenqi Liu, Fengjuan Fan, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 5
Predictive Biomarkers and Resistance Mechanisms of Checkpoint Inhibitors in Malignant Solid Tumors
Luciana Alexandra Pavelescu, Robert Mihai Enache, Oana Alexandra Roşu, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 17, pp. 9659-9659
Open Access | Times Cited: 5
Luciana Alexandra Pavelescu, Robert Mihai Enache, Oana Alexandra Roşu, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 17, pp. 9659-9659
Open Access | Times Cited: 5
Non‐Genetic Biomarkers in Merkel Cell Carcinoma: Prognostic Implications and Predictive Utility for Response to Anti‐PD ‐(L)1 Immune Checkpoint Inhibitors
David L. Drum, Anika G. Jallorina, Leo Q. Wan, et al.
Experimental Dermatology (2025) Vol. 34, Iss. 1
Closed Access
David L. Drum, Anika G. Jallorina, Leo Q. Wan, et al.
Experimental Dermatology (2025) Vol. 34, Iss. 1
Closed Access
A retrospective study of pembrolizumab plus chemotherapy for head and neck cancer patients: influence of response in combination phase on subsequent maintenance phase
Ken Saijo, Hiroo Imai, Yuki Kasahara, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Ken Saijo, Hiroo Imai, Yuki Kasahara, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
The Essentials of Multiomics
John L. Marshall, Beth N. Peshkin, Takayuki Yoshino, et al.
The Oncologist (2022) Vol. 27, Iss. 4, pp. 272-284
Open Access | Times Cited: 19
John L. Marshall, Beth N. Peshkin, Takayuki Yoshino, et al.
The Oncologist (2022) Vol. 27, Iss. 4, pp. 272-284
Open Access | Times Cited: 19
Immunogenetic variations predict immune-related adverse events for PD-1/PD-L1 inhibitors
Zhaodan Xin, Liting You, Feifei Na, et al.
European Journal of Cancer (2023) Vol. 184, pp. 124-136
Open Access | Times Cited: 11
Zhaodan Xin, Liting You, Feifei Na, et al.
European Journal of Cancer (2023) Vol. 184, pp. 124-136
Open Access | Times Cited: 11
Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis
He Li, Lei Yang, Yuanyuan Wang, et al.
BMC Bioinformatics (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 11
He Li, Lei Yang, Yuanyuan Wang, et al.
BMC Bioinformatics (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 11
Single-cell RNA sequencing in cancer research: discovering novel biomarkers and therapeutic targets for immune checkpoint blockade
Boyu Sun, Ziyu Xun, Nan Zhang, et al.
Cancer Cell International (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 11
Boyu Sun, Ziyu Xun, Nan Zhang, et al.
Cancer Cell International (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 11
Application of Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma: Current Status, Challenges, and Future Directions
Lingxiang Ran, Rui Zhao, Li Yu, et al.
(2025) Vol. 1, Iss. 1, pp. 1-54
Closed Access
Lingxiang Ran, Rui Zhao, Li Yu, et al.
(2025) Vol. 1, Iss. 1, pp. 1-54
Closed Access
Combination of cadonilimab (PD-1/CTLA-4 bispecific antibody) and apatinib as salvage therapy achieves partial response in MSI-H advanced gastric cancer: a case report
Jiayu Zhao, Xiaoxiao Li, Xiaoyuan Sun, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Jiayu Zhao, Xiaoxiao Li, Xiaoyuan Sun, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Immunotherapy Combined With Radiation Therapy for Genitourinary Malignancies
Jacob Ukleja, Erika Kusaka, David T. Miyamoto
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 26
Jacob Ukleja, Erika Kusaka, David T. Miyamoto
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 26
Hypofractionated Stereotactic Re-irradiation and Anti-PDL1 Durvalumab Combination in Recurrent Glioblastoma: STERIMGLI Phase I Results
Damien Pouessel, S. Ken, Valérie Gouazé‐Andersson, et al.
The Oncologist (2023) Vol. 28, Iss. 9, pp. 825-e817
Open Access | Times Cited: 9
Damien Pouessel, S. Ken, Valérie Gouazé‐Andersson, et al.
The Oncologist (2023) Vol. 28, Iss. 9, pp. 825-e817
Open Access | Times Cited: 9
